Q-omics provides the consensus-scored NKX3-2 profile across patient tissues and cancer cell-line models. NKX3-2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NKX3-2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, NKX3-2 RNA expression shows 16,729 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where NKX3-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX3-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX3-2 survival associations across molecular data types. NKX3-2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX3-2 RNA expression–survival associations across cancer types. High NKX3-2 expression shows unfavorable associations in KIRP, UVM, ACC, LIHC, LGG and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NKX3-2 RNA expression.
This table summarizes NKX3-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NKX3-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX3-2 shows lower tumor expression in COAD and higher tumor expression in LUAD, BLCA, HNSC, LUSC and BRCA. The LUAD box plot shows higher NKX3-2 RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with NKX3-2 in patient tissues and cancer cell lines. In patient samples, NKX3-2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX3-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
